Drugs / Glucose
Glucose
also known as
Panhematin · Sodium · Uric Acid · Glucose Monohydrate · Glucose PROAMP 30%, Laboratoires AGUETTANT · hematin for injection · hemin · hemin for injection
Trials 39 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT05603364 | Nov 2022 → Jun 2023 | — | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT02866435 | Nov 2016 → Sep 2019 | hypoglycemia | University of Minnesota | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03905408 | Sep 2019 → Feb 2021 | — | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 1 | NCT01323335 | Mar 2009 → Jan 2014 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1 | NCT00823108 | Mar 2009 → Oct 2010 | infectious disease with sepsis | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 1 | NCT00213551 | Apr 2004 → Jun 2008 | — | University Hospital, Rouen | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05627479 | Dec 2024 → Jan 2026 | bone disorder | NYU Langone Health | Withdrawn | No outcome recorded |
| Phase 2 | NCT06469970 | Nov 2024 → Mar 2027 expected | — | Centre Hospitalier Régional Metz-Thionville | Recruiting | No outcome recorded |
| Phase 2 | NCT04129190 | Oct 2019 → Jan 2020 | gestational diabetes | Isra University | Unknown | No outcome recorded |
| Phase 2 | NCT04001036 | Sep 2019 → Aug 2022 | end stage renal failure | Iperboreal Pharma Srl | Terminated | No outcome recorded |
| Phase 2 | NCT02180412 | Apr 2014 → Feb 2022 | porphyria | The University of Texas Medical Branch, Galveston | Completed | No outcome recorded |
| Phase 2 | NCT01242904 | Sep 2010 → Feb 2015 | end stage renal failure | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| Phase 2 | NCT00858182 | May 2009 → Oct 2012 | end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00467610 | May 2007 → Dec 2008 | myelodysplastic syndrome | Rush University Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT00426114 | — | — | University Hospital, Ghent | Withdrawn | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00860366 | Jun 2011 → Aug 2013 | ischemic stroke | Angel Chamorro, MD | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02374281 | Dec 2014 → Apr 2015 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 3 | NCT02325583 | Jan → Oct 2014 | epilepsy, hydrocephalus | Baskent University | Completed | No outcome recorded |
| Phase 3 | NCT00062972 | Sep 1999 → Aug 2002 | multiple sclerosis | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 45 trials | ||||||
| Phase 4 | NCT04035564 | Mar 2018 → Mar 2020 | — | Hospital del Niño "Dr. Federico Gomez Santos" | Completed | No outcome recorded |
| Phase 4 | NCT04106882 | Jun 2015 → Sep 2022 | — | Stony Brook University | Unknown | No outcome recorded |
| Phase 4 | NCT04840095 | Jun 2015 → Sep 2023 | — | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01384656 | Feb 2011 → Feb 2012 | acute coronary syndrome | Yonsei University | Completed | No outcome recorded |
| Phase 4 | NCT00278057 | May 2003 | — | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT06955130 | Jul 2026 → Apr 2029 expected | obesity disorder, type 2 diabetes mellitus | Rutgers, The State University of New Jersey | Not yet recruiting | No outcome recorded |
| — | NCT07350135 | Nov 2025 → Nov 2028 expected | — | Ain Shams University | Active not recruiting | No outcome recorded |
| — | NCT06155825 | Dec 2023 → Dec 2024 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT07014735 | Apr 2023 → May 2026 | hyperglycemia, torsades de pointes, type 2 diabetes mellitus | Richmond Pharmacology Limited | Terminated | No outcome recorded |
| — | NCT03690232 | Oct 2018 → Jun 2020 | osteoarthritis, knee | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT03486015 | Mar 2016 → Apr 2017 | — | Region Örebro County | Completed | No outcome recorded |
| — | NCT02411318 | Sep 2014 → Dec 2019 | defective phagocytic cell chemotaxis | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT01919788 | Aug 2013 → Apr 2014 | hypoglycemia, type 1 diabetes mellitus | University of Aarhus | Completed | No outcome recorded |
| — | NCT01931020 | Jul 2013 → Jul 2014 | — | Lady Hardinge Medical College | Completed | No outcome recorded |
| — | NCT01514253 | Feb → May 2012 | — | The Baruch Padeh Medical Center, Poriya | Unknown | No outcome recorded |
| — | NCT01289808 | Feb → May 2011 | perinatal disease | The Baruch Padeh Medical Center, Poriya | Terminated | No outcome recorded |
| — | NCT01308359 | Jan 2011 → Jan 2012 | — | Tel-Aviv Sourasky Medical Center | Unknown | No outcome recorded |
| — | NCT00788242 | Jan 2009 → Dec 2013 | aortic valve stenosis, coronary artery disorder, heart failure | Christoph Ellenberger | Completed | No outcome recorded |
| — | NCT00005889 | Oct 1999 → ? | hyperglycemia | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| — | NCT00004451 | Mar 1998 → ? | Parkinson disease | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 50 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05737927 Comparator | Sep → Nov 2020 | obesity disorder | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Phase 1 | NCT04409665 Comparator | Jan 2020 → Mar 2022 | newborn respiratory distress syndrome | Medical University of Warsaw | Unknown | No outcome recorded |
| Phase 1 | NCT05713773 Comparator | Oct → Dec 2019 | metabolic syndrome X, obesity disorder | Aphaia Pharma US LLC | Completed | No outcome recorded |
| Phase 1 | NCT03315338 Background | Sep 2017 → Feb 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01300260 Background | Feb → Aug 2011 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00800085 Comparator | Oct 2006 → Oct 2014 | type 1 diabetes mellitus | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT03337477 Comparator | Feb → Dec 2018 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02607839 Comparator | Feb 2013 → Apr 2015 | — | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT01516138 Comparator | Feb 2012 → Mar 2013 | — | Xijing Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00755456 Comparator | Jan 2008 → Sep 2012 | end stage renal failure | Iperboreal Pharma Srl | Completed | No outcome recorded |
| Phase 2 | NCT00755404 Comparator | Jun 2007 → Oct 2013 | diabetes mellitus, end stage renal failure | Iperboreal Pharma Srl | Withdrawn | No outcome recorded |
| Phase 2 | NCT00282867 Comparator | May 2006 → Feb 2008 | hyperglycemia, ischemic stroke | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00814008 Background | Mar 1999 → Apr 2000 | retinal disorder, type 1 diabetes mellitus | Medical University of Vienna | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03860688 Background | May 2019 → Dec 2021 | hyperlipidemia | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03883763 Background | Apr 2022 → Apr 2023 | — | Cristália Produtos Químicos Farmacêuticos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT05962255 Comparator | Feb 2022 → Apr 2024 | heart failure | Wroclaw Medical University | Completed | No outcome recorded |
| Phase 3 | NCT00965406 Background | Aug 2010 → Dec 2013 | acute coronary syndrome | University of Monastir | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT07189091 Comparator | Oct 2025 → Apr 2028 expected | — | University Hospital, Antwerp | Recruiting | No outcome recorded |
| Phase 4 | NCT06624956 Comparator | Sep 2024 → Sep 2025 | hyperglycemia | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT06739473 Background | Jan 2023 → Dec 2024 overdue | obesity disorder | Turku University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05496764 Comparator | Dec 2021 → Jan 2023 | carpal tunnel syndrome | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT03666546 Comparator | Nov 2018 → Mar 2019 | type 2 diabetes mellitus | Fresenius Kabi | Completed | No outcome recorded |
| Phase 4 | NCT03126084 Comparator | May → Nov 2017 | — | Bozyaka Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02657252 Comparator | Jan 2015 → Sep 2016 | telangiectasis, varicose disease | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
| Phase 4 | NCT02054325 Comparator | Sep 2012 → Dec 2014 | varicose disease | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
| Phase 4 | NCT01387477 Comparator | Jun 2011 → Jun 2012 | hypoglycemia | Institut d'Anesthesiologie des Alpes Maritimes | Withdrawn | No outcome recorded |
| Phase 4 | NCT01253889 Comparator | Dec 2010 → Jun 2013 | — | Children's & Women's Health Centre of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT01209403 Comparator | Sep 2010 → Jul 2011 | end stage renal failure | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT00709839 Background | Jun → Oct 2008 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00558155 Background | Jun 2001 → Dec 2005 | gastric cancer, malignant pancreatic neoplasm | Jagiellonian University | Completed | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07114263 Background | Aug 2025 → Feb 2026 overdue | — | Tanta University | Not yet recruiting | No outcome recorded |
| — | NCT06061783 Comparator | Nov 2023 → Sep 2024 | — | Hospital Civil de Guadalajara | Unknown | No outcome recorded |
| — | NCT05874804 Comparator | Sep 2023 → Oct 2025 | end stage renal failure | Triomed AB | Completed | No outcome recorded |
| — | NCT04967118 Comparator | May 2023 → May 2024 | — | University of Oulu | Unknown | No outcome recorded |
| — | NCT05589441 Background | Oct 2022 → Oct 2023 | — | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT05464966 Background | Jun 2022 → May 2023 | — | Yangzhou University | Completed | No outcome recorded |
| — | NCT04664010 Background | Feb 2020 → Sep 2022 | COVID-19 | Xi'an International Medical Center Hospital | Completed | No outcome recorded |
| — | NCT03273881 Comparator | Oct 2017 → Dec 2023 | diabetes mellitus, obstetric disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| — | NCT02622854 Comparator | Jun 2016 → Aug 2020 | acute pancreatitis | University Medical Centre Ljubljana | Completed | No outcome recorded |
| — | NCT02166359 Comparator | Jun 2014 → Mar 2019 | end stage renal failure | Dong-A University | Completed | No outcome recorded |
| — | NCT02036372 Comparator | Jan 2014 → Jan 2017 | type 2 diabetes mellitus | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT01706341 Comparator | Oct 2012 → Oct 2013 | — | Nagoya City University | Unknown | No outcome recorded |
| — | NCT01402037 Background | Jul 2011 → Jul 2015 | type 1 diabetes mellitus | University Hospital Brussels | Unknown | No outcome recorded |
| — | NCT01170858 Comparator | Aug 2010 → Aug 2014 | end stage renal failure | Yonsei University | Completed | No outcome recorded |
| — | NCT02305069 Background | Oct 2009 → Oct 2011 | muscular atrophy, obesity disorder | University of Nottingham | Completed | No outcome recorded |
| — | NCT00899483 Comparator | Jul 2009 → Jul 2012 | type 2 diabetes mellitus | University Hospital Birmingham | Unknown | No outcome recorded |
| — | NCT01213563 Comparator | Jan 2009 → Sep 2010 | type 2 diabetes mellitus | Imperial College London | Terminated | No outcome recorded |
| — | NCT00761059 Comparator | Oct 2008 → Dec 2009 | — | University of Cologne | Unknown | No outcome recorded |
| — | NCT01225159 Background | Sep 2008 → Mar 2009 | hypoglycemia, nosocomial infection | Prince of Songkla University | Terminated | No outcome recorded |
| — | NCT00431665 Background | Jul 1999 → Jun 2000 | — | Medical University of Vienna | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 89 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glucose | “A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused” NCT01225159 ↗83“Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients.” NCT00858182 ↗ “Intravenous injection of 8U of insulin complex 10% glucose solution 250 ml before the start of the hepatic phase was completed in 15 minutes.” NCT05589441 ↗ “Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.” NCT05627479 ↗ “glucose-insulin-potassium (GIK) consists of 20% glucose (200 g/L), 66.7 U/L regular insulin and 80 mmol/L potassium chloride (KCl).” NCT01516138 ↗ “it will be glucose solution 5% 500ml + injectable water 500ml intravenous every 8 hours for a total of 3,600ml daily.” NCT06061783 ↗ “Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland)” NCT00558155 ↗ “200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks” NCT01242904 ↗ “Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A).” NCT01213563 ↗ “GIK solution (potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)” PMID 22986417 ↗ Sep 2012 “PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges” NCT00755404 ↗ “infusion of 5% glucose and insulin, to maintain blood glucose at 5-8 mmol/l” NCT02622854 ↗ “together with 20 % glucose to maintain normal glucose values” NCT06739473 ↗ “Glucose is administered to both groups as routine care.” NCT02180412 ↗ “and 1 ml glucose 5% with total volume of 3ml.” NCT07114263 ↗ “GIK (glucose -insulin - potassium) infusion” NCT02036372 ↗ “Glucose-insulin-potassium” NCT00823108 ↗ “1000 ml of Glucose 10%” NCT00965406 ↗ |
| Known as | Glucose Monohydrate | “Glucose Monohydrate” NCT03666546 ↗ |
| Known as | Glucose PROAMP 30%, Laboratoires AGUETTANT | “Glucose PROAMP 30%, Laboratoires AGUETTANT” NCT02374281 ↗ |
| Known as | hematin for injection | “The objective of this study is to evaluate the safety and efficacy of Panhematin® (hematin for injection) in the treatment of adult patients” NCT00467610 ↗ |
| Known as | hemin | “This study aims to provide high quality evidence for the effectiveness and safety of hemin (PanhematinTM , Recordati) for treatment of acute attacks of porphyria.” NCT02180412 ↗ |
| Known as | hemin for injection | “We are proposing a novel approach for the treatment of patients with low-risk MDS using heme supplementation with Panhematin® (hemin for injection).” NCT00467610 ↗ |
| Known as | Panhematin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00467610 ↗ |
| Known as | Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04035564 ↗ |
| Known as | Uric Acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01323335 ↗ |
| Action | Inhibit | “presumably, as a result of the inhibition of aminolevulinic acid synthetase” NCT00467610 ↗ |
| Modality | Small molecule | “Panhematin® is an iron-containing metalloporphyrin” NCT00467610 ↗ |
| Route | Intravenous | “[U-13C]glucose IV beginning at zero hour” NCT00005889 ↗ |